Efficient photocathodic protection enabled by a multi-dimensional quaternary hybrid superstructure

Yunpeng Liu(Shenyang Institute of Automation), Zijun Ren(Xi'an Jiaotong University), Jiangtao Feng(Xi'an Jiaotong University), Bo Hou(Electric Power University), Hao Xu(Xi'an Jiaotong University), Changzheng Lin(Zhejiang University), Zhenyu Wang(Shandong University), Wenlong Zhang(Xi'an Jiaotong University), Wei Yan(Xi'an Jiaotong University), Xi Wang(Tianjin University of Traditional Chinese Medicine), Jianmin Lü(Dalian Institute of Chemical Physics)
Chemical Engineering Journal
November 27, 2020
10.1016/j.cej.2020.127858
Cited by 28

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412